Reason for request
Inclusion on the list of medicines reimbursed by National Health Insurance and approved for use by hospitals.
Clinical Benefit
| Substantial |
The actual benefit of RANEXA in this indication is substantial. |
Clinical Added Value
| no clinical added value |
RANEXA should be used only by patients with stable angina that is inadequately controlled or who are intolerant to betablockers and/or calcium channel blockers.
Given the data available, RANEXA does not provide any improvement in actual benefit (IABV) in the management of these patients. |
eNq1mF1v2jAUhu/5FVHuSYB+wRSoNlY2pFZlFLRpN5VJDsUs2Omxzcd+/RwCKp0ctTX4MrHznhOf14+PHF2vF6m3BBSUs7ZfD2q+ByzmCWVPbX886lWb/nWnEs3JkrxMa+h5Qb3ue3FKhGj7+WgwAcJE8Ovu9ivo7wH9TsWL+GQOsXw1T0maBt+JmN2RLJ/jRUtOE28BcsaTtp8puX3rRUKizqKz4vhHZCSGKNy9ORydP54fvo/CXOwdqkoA3hL2ZBQFZqUZK0RgskskPHHclOR7ZqVNxRAEVxjDgMjZAPmSJpAYQ0xJKsAqyHSVPAAuU5B5EKN4OI8XwkqczMl6CM99c9Kf9WhXrmW1Vq1ftWqN8/PLq4vWxYVVKDxYKnMV9E+E8WOzedZo1UJgIRIGa2JZmQFHSVJHNaGi+9pWjuIgPL9Z+4SKLCWbYC4y26UiSPQwoN787n4k/4ORLqlI9Zr9p89UmoYfzHq8g4WjjHMWdblisoQZvaHtQnQ5k7Aur6gd5uR650UK4nSyfzkzI36gJimNbYGmkaNAyPGwX86z06HgCxEwRncs+ElZwlfi9Iw5rKmj7LMtJo2iGSb1x0areVm3JH6+hX5rA5WcLjcKeQahpg8Vx0Clz6b8WJxoT5ql9o48kRm3HQ6PSQolPU7VkivahfuWzJnP3e2hYsAo+u1mZGuOHwpw87B9NErTpL0vqx1zXYBcO7E074/7utjeTppfhWZszKTMxKcwnBFRFUSvUDDFEwP94AR113Q7OaaLtqWAoqPUJ8Vp9/7a2G6vtw7xYxvT3fe7BtgYQ6KCI+pQkNgZL/s3p0fwS1fqLO3BK2a4C7PtIImknLnqbdTEqHgU9HVZWQ81G+6nU1py/1Fqyygs7l46lSjM7106lX8VJd66
LVZcHQTDNBZ7jnMa
